Biomarker based treatment selection in cancer

Purpose and goal

In our biomarker studies we have identified a molecular subtype of cancer that responds to a specific treatment. Our primary goals of the current project were to evaluate these findings in a larger clinical cohort, and to develop a method that can be used for more accurate subtyping of clinical samples. Both of these goals have been accomplished to a large part. We have analysed a large cohort of clinical samples, and we have established methods for analysis of clinical samples. Further, we have initiated discussions with potential investors and collaborators within the pharma industry.

Expected results and effects

Once development is completed, our analysis methods can be used in healthcare to better support responsible clinicians in their therapy decisions. During this sub-project we have developed our analysis methods and evaluated our hypothesis in a larger clinical material. The results are that we have increased our knowledge about how to best analyse the tumour samples, and that we have further improved our analysis methods. Further, we have confirmed our previous findings in the clinical material and validated the cancer subtype that we previously linked to a specific type of treatment.

Planned approach and implementation

In this sub-project we have evaluated different methods to analyse our biomarkers in clinical samples. This work has resulted in that we now have identified the optimal methods that will give us even more information than we originally aimed for. Further, we used the selected methods to analyse a larger clinical cohort of tumour samples. We are currently optimising the selected analysis methods together with CROs and academic collaborators, to ensure high quality and reproducibility in the generated output